• Korean Journal of Plant Taxonomy
• /
• v.40 no.4
• /
• pp.274-277
• /
• 2010

This study was performed to report the augmented wild populations of Forsythia koreana (Rehder) Nakai and Abeliophyllum distichum Nakai in Korea. Forsythia koreana was found in Budong-myeon, Cheongsong-gun, Gyeongsangbuk-do. The overall size of the natural habitat of Forsythia koreana is $5m{\times}5m$. A total of 12 individuals were recorded in the wild, and 3 of them were in the seedling stage. The wild habitat is in a secondary forest, which is co-dominated by Pinus densiflora Siebold & Zucc and Robinia pseudoacacia L, with 15% coverage. The coverage of the shrub layer is 40% and is dominated by Spiraea prunifolia for. simpliciflora Nakai. The natural habitat of Abeliophyllum disitichum, which is recorded in Uisong-up, Gyeongsangbuk-do, is distributed in sites characterized by boulders along streams, with a patchwork of 15 scattered areas over a habitat size of $50m{\times}15m$. Quercus variabilis Blume is a dominant species in this habitat, with this species dominating at the sub-tree layer. Celtis aurantiaca Nakai also dominates at the shrub layer. The natural ranges of these two species in Korea were mapped based on the terms of the extent of occupancy (EoO).

• Korean Journal of Biological Psychiatry
• /
• v.5 no.1
• /
• pp.34-45
• /
• 1998

We provide the reader with a brief introduction to the neurobiology of neuropeptides. Several comprehensive reviews of the distribution and neurochemical, neurophysiological, neuropharmacological and behavioral effects of the major neuropeptides have recently appeared. In reviews of the large number of neuropeptides in brain and their occurance in brain regions thought to be involved in the pathogenesis of major psychiatric disorders, investigators have sought to determine whether alternations in neuropeptide systems are associated with schizophrenia, mood disorders, anxiety disorders, alcoholism and neurodegenerative disease. There is no longer any doubt that neuropeptide-containing neurons are altered in several neuropsychiatric disorders. One of the factors that has hindered neuropeptide research to a considerable extent is the lack of pharmacological agents that specifically alter the synaptic availability of neuropeptides. With the exception of naloxone and naltrexone, the opiate-receptor antagonists, there are few available neuropeptide- receptor antagonists. Two independent classes of neuropeptide-receptor antagonists has been expected to be clinically useful. Naltrexone, a potent ${\mu}$-receptor antagonist, has been used successfully to reduce the need for alcohol consumption. And cholecycstokinin antagonists are now in development as a new class of anxiolytics, which would be expected to be free from tolerance and physical dependence and lack of sedation. In this review, we deal with these two kinds of neuropeptide system, the opioid system and cholesystokinins in the brain. The role of opioid systems in the reinforcement after alcohol consumtion and that of cholesystokinins in the pathogenesis of anxiety will be discussed briefly. As we know, the future for neuropeptides in psychiatry remains bright indeed.